Shilpa Medicare gets FDA nod for generic cancer treatment tablets
New Delhi: Shilpa Medicare has received approval from the US health regulator for generic Capecitabine tablets used for treatment of various types of cancers.
The company has received an approval from the United States Food and Drug Administration (USFDA) for Capecitabine tablets USP in the strengths of 150 mg and 500 mg, Shilpa Medicare said in a BSE filing.
The product is a generic version of Hoffmann-La Roche Inc's Xeloda tablets in the same strengths, it added.
Capecitabine tablets are used to treat breast and colorectal cancers. It works by slowing or stopping the growth of cancer cells.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd